1 to 10 of 47 literature results

• Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

  BACKGROUND: Gastrointestinal stromal tumour is the most common sarcoma of the intestinal tract. Imatinib mesylate is a small molecule that inhibits ac…

  Authors: Ronald P Dematteo, Karla V Ballman, Cristina R Antonescu, Robert G Maki, Peter W T Pisters, George D Demetri, Martin E Blackstein, Charles D Blanke, Margaret von Mehren, Murray F Brennan,…

  Source: Lancet. 2009 Mar 28

  View Full Text

• Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?

  Currently, combination chemotherapy represents the standard of care treatment for patients with metastatic colorectal cancer in the United States. Des…

  Authors: Rachel Sanborn, Charles D Blanke

  Source: Seminars in oncology. 2005 Feb

  View Full Text

• Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.

  Despite initial efficacy of imatinib mesylate in most gastrointestinal stromal tumor (GIST) patients, many experience primary/secondary drug resistanc…

  Authors: Lori Rink, Yuliya Skorobogatko, Andrew V Kossenkov, Martin G Belinsky, Thomas Pajak, Michael C Heinrich, Charles D Blanke, Margaret von Mehren, Michael F Ochs, Burton Eisenberg,…

  Source: Molecular cancer therapeutics. 2009 Aug

  View Full Text

• Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.

  Imatinib mesylate is a selective inhibitor of a few tyrosine kinases including KIT, and it is the first effective treatment for gastrointestinal strom…

  Authors: Petri Bono, Andreas Krause, Margaret von Mehren, Michael C Heinrich, Charles D Blanke, Sasa Dimitrijevic, George D Demetri, Heikki Joensuu

  Source: Blood. 2004 Apr 15

  View Full Text

• State-of-the art therapy for gastrointestinal stromal tumors.

  Until recently, there were few effective therapeutic options for patients with gastrointestinal stromal tumors (GISTs). Most patients undergoing even …

  Authors: Charles D Blanke, Christopher L Corless

  Source: Cancer investigation. 2005

  View Full Text

• Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).

  INTRODUCTION: Patients with metastatic colorectal cancer who progress on standard chemotherapy have limited treatment options. New and effective drugs…

  Authors: Robert P Whitehead, Cathryn Rankin, Paulo M G Hoff, Philip J Gold, Kevin G Billingsley, Robert A Chapman, Lucas Wong, John H Ward, James L Abbruzzese, Charles D Blanke

  Source: Investigational new drugs. 2009 Oct

  View Full Text

• Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

  BACKGROUND: Therapy for gastrointestinal stromal tumors (GIST) has changed significantly with the use of imatinib mesylate (IM). Despite the success o…

  Authors: Burton L Eisenberg, Jonathan Harris, Charles D Blanke, George D Demetri, Michael C Heinrich, James C Watson, John P Hoffman, Scott Okuno, John M Kane, Margaret von Mehren

  Source: Journal of surgical oncology. 2009 Jan 1

  View Free Full Text

• Biomarkers in GIST: partly ready for prime-time use.

  Gastrointestinal stromal tumors, or GISTs, are now among the most treatable of solid malignancies. Assessing actual tumor response remains challenging…

  Authors: Charles D Blanke

  Source: Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Sep 15

  View Full Text

• A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.

  A phase I study of fixed-dose 5-fluorouracil (FU) and leucovorin (LCV), with excalating doses of the selective cyclooxygenase-2 (COX-2) inhibitor cele…

  Authors: Charles D Blanke, Nora C Mattek, Thomas G Deloughery, Dennis R Koop

  Source: Prostaglandins & other lipid mediators. 2005 Jan

  View Full Text

• Postchemotherapy hyperammonemic encephalopathy emulating ornithine transcarbamoylase (OTC) deficiency.

  A young patient with hepatocellular carcinoma receiving chemotherapy presented with encephalopathy. Evaluation of the patient revealed a metabolic pro…

  Authors: Joseph S Chan, Cary O Harding, Charles D Blanke

  Source: Southern medical journal. 2008 May

  View Full Text